EMEA-002748-PIP01-20 - paediatric investigation plan

Adenovirus encoding vascular endothelial growth factor C

Key facts

• Active Substance:
  Adenovirus encoding vascular endothelial growth factor C
• Therapeutic area:
  Other
• Decision number:
  P/0230/2020
• PIP number:
  EMEA-002748-PIP01-20
• Pharmaceutical form(s):
  Solution for injection
• Condition(s) / indication(s):
  Secondary lymphedema associated with the treatment of breast cancer
• Route(s) of administration:
  Ex vivo intranodal injection
• Contact for public enquiries:

  Herantis Pharma Plc

  E-mail: [e-mail]; Tel. [phone]

• Decision type:
  W: decision granting a waiver in all age groups for all conditions or indications
• Decision date:
  19/06/2020

Decision

P/0230/2020: EMA decision of 19 June 2020 on the granting of a product specific waiver for adenovirus encoding vascular endothelial growth factor C (AdAptVEGF-C) (EMEA-002748-PIP01-20)

AdoptedReference Number: EMA/303245/2020